Projects and grants

Last and current projects:

Transcription factor MITF – key regulator of proliferation and survival of melanoma cells a molecular target of antitumor therapy. (IGA MH CR no. NT/11229-3, 2010-2012), (J.Vachtenheim - principal investigator)

Hedgehog-GLI signalling: an indicator of the tumor biological behavior in melanoma, lung cancer and some other tumors and its blocking as an antitumor therapy (IGA MH CR no. NT/14005, 2013-2015), (J.Vachtenheim - principal investigator)

Transcription factor MITF as a possible target of the antitumor therapy of melanoma – importance of MITF level for tumor phenotype an therapy. (GAUK no. 172214, 2014-1016), (K. Vlčková - principal investigator, J.Vachtenheim - supervisor)

Combination of three low-molecular weight inhibitors of signaling pathways in one drug as an efficient and complete eradication of malignant melanoma cells (GAMA4-TAČR no. TG01010108, 2017-2019), (J.Vachtenheim - principal investigator)

Progres Q25. Institutional project of the Charles University Prague (2017-2021), (J.Vachtenheim - principal investigator)

Financial support from League against Cancer, Prague (in cooperation with the University Hospital Motol), 2019

Grants from League against Cancer, Prague (2021-2022, 2022-2023), (J.Vachtenheim - principal investigator)

Cooperatio. Institutional project of Charles University, fields Medical Biochemistry, Metabolic Diseases, Oncology (2022-up to now), (J.Vachtenheim - principal investigator)